Group A Streptococcal Virulence Factors and Vaccine Development—An Update
Microorganisms · 03.02.2026 · 14 (2) · 357
DOI: 10.3390/microorganisms14020357 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Microorganisms, online erschienen am 03.02.2026. Verfasst von Shunyi Fan und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Medicine, School of Medical Sciences, The University of Auckland, Auckland 1010, New Zealand. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 173 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Royal Society Te Apārangi, Auckland Medical Research Foundation, PhD scholarship from the China Scholarship Council (CSC).
Abstract (Originalsprache)
A Group A Streptococcus (GAS, Streptococcus pyogenes) is an exclusively human pathogen whose virulence is driven by a diverse array of surface structures, secreted toxins, and immune evasion mechanisms. Central to its pathogenicity is the M protein, a surface-anchored molecule that inhibits phagocytosis by interfering with complement deposition and binding host factors such as fibrinogen. GAS also secretes a wide range of toxins and enzymes that damage tissues and disrupt host defences. Streptolysin O and streptolysin S are potent cytolysins that lyse immune cells and contribute to tissue necrosis. Pyrogenic exotoxins (such as SpeA and SpeC) act as superantigens, triggering massive, dysregulated T cell activation and cytokine release, an underlying mechanism in streptococcal toxic shock syndrome. Additional factors like DNases and streptokinase facilitate bacterial spread by breaking down host tissue and counteracting neutrophil extracellular traps (NETs). Immune evasion is further supported by the production of enzymes that interfere with complement functions, like the cleavage of chemokines and the targeting of antibodies. Together, these virulence determinants allow GAS to cause a wide spectrum of diseases, ranging from uncomplicated pharyngitis and impetigo to invasive conditions like necrotising fasciitis and sepsis. This review provides a timely overview of the important GAS virulence factors and an update on the current vaccine landscape.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Molecular Medicine, School of Medical Sciences, The University of Auckland, Auckland 1010, New Zealand.
- Maurice Wilkins Centre for Molecular Biodiscovery, Auckland 1010, New Zealand.
ORCID-Profile: Catherine Jia-Yun Tsai, Jacelyn Mei San Loh, Thomas Proft
Förderung
- Royal Society Te Apārangi
- Auckland Medical Research Foundation
- PhD scholarship from the China Scholarship Council (CSC)
- the Maurice Wilkins Center for Molecular Biodiscovery (MWC)
- Royal Society New Zealand
- Maurice Wilkins Center for Molecular Biodiscovery
- China Scholarship Council
Zitieren
APA
Fan, S., Tsai, C. J., Loh, J. M. S., & Proft, T. (2026). Group A Streptococcal Virulence Factors and Vaccine Development—An Update. Microorganisms, 14(2), 357. https://doi.org/10.3390/microorganisms14020357
Vancouver
Fan S, Tsai CJ, Loh JMS, Proft T. Group A Streptococcal Virulence Factors and Vaccine Development—An Update. Microorganisms. 2026;14(2):357. doi:10.3390/microorganisms14020357
BibTeX
@article{Fan2026,
author = {Fan, Shunyi and Tsai, Catherine Jia-Yun and Loh, Jacelyn Mei San and Proft, Thomas},
title = {Group A Streptococcal Virulence Factors and Vaccine Development—An Update},
journal = {Microorganisms},
year = {2026},
volume = {14},
number = {2},
pages = {357},
doi = {10.3390/microorganisms14020357}
}
EUVIMED